Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC/Dietary Supplement Combos Cited In FDA Warning Letters

This article was originally published in The Tan Sheet

Executive Summary

The presence of acetaminophen in OTC/dietary supplement combination products renders them drugs, FDA says in recent warning letters to two companies.
Advertisement

Related Content

Will Bayer Supplement-Drug Combo Draw Other Firms Into New Market?
Bayer’s Aspirin/Phytosterols Combination May Draw FDA Warning
Dietary Supplement Industry Registration, User Fees Mulled By Trade Groups
OTC/Supplement Co-Packaging Policy In The Works At FDA
Bayer Women’s Aspirin Plus Calcium Available Nationwide In February
OTC/Supplement Combo Guidance, Sale Urged By Rep. Burton
Supplement/OTC Combos Have Precedents In Other Categories, Firms State
OTC/Dietary Supplement Combination Guidance “Unlikely” – FDA
OTC/Supplement Combination Marketing Guidance Requested By NNFA
OTC/Supplement Combination Marketing Guidance Requested By NNFA

Topics

Advertisement
UsernamePublicRestriction

Register

PS093181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel